
Elgia Therapeutics: Innovating biopharma solutions for chronic inflammatory and fibrotic diseases.
Elgia Therapeutics, founded to address chronic inflammatory and fibrotic diseases, is a biotechnology company focused on healthcare, therapeutics, pharmaceuticals, and medicine. The company's core mission is to innovate biopharma solutions by leveraging its novel target platform for metabolic inflammation and fibrosis. Elgia has discovered how metabolic stress drives these conditions and has identified unique protein targets for small molecule drug discovery, aiming to create groundbreaking medicines for debilitating chronic diseases.
Notable figures affiliated with Elgia Therapeutics include Michael Jaramillo. The company has made significant strides in the biopharmaceutical industry by combining pioneering biological insights with robust R&D expertise. Elgia's key achievements include the identification of untapped protein targets and the development of innovative therapeutic approaches. Its impact lies in advancing treatment options for chronic inflammatory and fibrotic diseases, potentially transforming patient outcomes and improving quality of life.

Halia Therapeutics

Exalys Therapeutics

Eolo Pharma
eolo-pharma.com

Pliant Therapeutics
pliantrx.com

Aristea Therapeutics

Selva Therapeutics

Therini Bio
therinibio.com

Eikon Therapeutics
eikontx.com

EpiBiologics
epibiologics.com

Complexa

Blade Therapeutics

Elastrin Therapeutics
elastrin.com

Lassen Therapeutics

Ingenia Therapeutics
ingeniatx.com

Spyre Therapeutics
aeglea.com
Companies similar to Elgia Therapeutics include Halia Therapeutics, Exalys Therapeutics, Eolo Pharma and Pliant Therapeutics.
Elgia Therapeutics was founded in 2019.
Elgia Therapeutics' headquarters is located in San Diego, CA, US.
Elgia Therapeutics' most recent funding round was for $2.3M (USD) in April 2020.
As of Apr 28, 2020, Elgia Therapeutics has raised a total of $2.3M (USD).
Elgia Therapeutics has 7 employees as of Feb 5, 2024.